Skip to main content
SpringerLink
Log in

The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis

  • Correspondence
  • Published:
Intensive Care Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T et al (2022) Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial. Intensive Care Med 48(3):311–321

    Article  CAS  Google Scholar 

  2. Committee for Medicinal Products for Human Use (2016) Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. European Medicines Agency. https://www.ema.europa.eu/en/use-pharmacokinetics-pharmacodynamicsdevelopment-antibacterial-medicinal-products. Accessed 28 Feb 2022

  3. Wicha SG, Martson AG, Nielsen EI, Koch BCP, Friberg LE, Alffenaar JW et al (2021) From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther 109(4):928–941

    Article  CAS  Google Scholar 

  4. El-Haffaf I, Caissy JA, Marsot A (2021) Piperacillin-tazobactam in intensive care units: a review of population pharmacokinetic analyses. Clin Pharmacokinet 60(7):855–875

    Article  CAS  Google Scholar 

  5. Weinelt FA, Stegemann MS, Theloe A, Pfäfflin F, Achterberg S, Schmitt L et al (2021) Development of a model-informed dosing tool to optimise initial antibiotic dosing-A translational example for Intensive Care Units. Pharmaceutics 13(12):2128

    Article  CAS  Google Scholar 

Download references

Funding

MG is a postdoctoral research fellow of KU Leuven, Belgium (Grant number PDMT2/21/077). ED is a postdoctoral research fellow of the Research Foundation—Flanders (FWO), Belgium (Grant number 12X9420N).

Author information

Authors and Affiliations

  1. Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium

    Matthias Gijsen, Erwin Dreesen & Isabel Spriet

  2. Pharmacy Department, University Hospitals Leuven, Leuven, Belgium

    Matthias Gijsen & Isabel Spriet

  3. Department of General Internal Medicine, Medical Intensive Care Unit, University Hospitals Leuven, Leuven, Belgium

    Joost Wauters

  4. Department of Intensive Care Medicine, University Hospitals Leuven, Leuven, Belgium

    Yves Debaveye

  5. Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000, Leuven, Belgium

    Joost Wauters

  6. Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium

    Yves Debaveye

Authors
  1. Matthias Gijsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erwin Dreesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joost Wauters
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yves Debaveye
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isabel Spriet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Gijsen.

Ethics declarations

Conflicts of interest

ED has received consultancy fees from argenx and Janssen (all honoraria/fees paid to the University). The other authors have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gijsen, M., Dreesen, E., Wauters, J. et al. The TARGET trial as a plea for model-informed precision dosing of piperacillin/tazobactam in patients with sepsis. Intensive Care Med 48, 768–769 (2022). https://doi.org/10.1007/s00134-022-06679-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00134-022-06679-0

Search

Navigation